Tusamitamab ravtansine

At the 2024 WCLC, 7,000+ clinicians and scientists gathered to review impactful abstracts on lung cancer treatments, including novel perioperative strategies for resectable lung cancer and the use of tyrosine kinase inhibitors, bispecific antibodies, and ADCs in advanced NSCLC and SCLC. Key findings included superior event-free survival with perioperative nivolumab, high pathologic response rates with ADCs in localized NSCLC, and promising outcomes with EGFR-MET bispecific antibodies and HER2-targeted therapies. The conference also highlighted the potential of ADCs in SCLC and the need for improved biomarker development and patient selection tools.

The CARMEN-LC03 trial did not meet its primary endpoints of progression-free and overall survival with tusamitamab ravtansine vs docetaxel in previously treated advanced nonsquamous NSCLC patients, leading to study termination in Dec 2023. Trends toward improved survival were observed in subgroups with high CEACAM5 expression, and a favorable safety profile was noted for tusamitamab ravtansine.

CEACAM5 drugs market to grow significantly due to rising cancer diagnoses and clinical trials; no CEACAM5 drugs currently approved. Key companies developing CEACAM5 drugs include Merck KGaA, Sanofi, and Roche. Emerging therapies like SGM-101 and M9140 show promise in clinical trials.

The phase 3 CARMEN-LC03 trial found that tusamitamab ravtansine, an ADC targeting CEACAM5, did not significantly improve PFS or OS compared to docetaxel in advanced nonsquamous NSCLC patients with CEACAM5 expression. The study, which randomized 389 patients, showed similar PFS and OS outcomes between the two treatment arms, leading to early termination. Safety data indicated fewer grade 3 or higher AEs and treatment discontinuations with tusamitamab ravtansine. The trial was discontinued in December 2023, but patients benefiting from treatment could continue receiving tusamitamab ravtansine.